Grace Blacker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grace Blacker has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Michal Caspi Tal
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA
3 shared publications - Irving L. Weissman
Stanford University
2 shared publications - Sarah Galloway
Institute for Stem Cell Biology & Regenerative Medicine, Stanford University School of Medicine, Stanford, USA
2 shared publications - Annalena Reuss
Eberhard Karls Universitt Tblngen,Zentrum fr Datenverarbeitung,Tbingen,Germany
1 shared publication - Brandon T. Lee
Department of Biological Engineering, Massachusetts Institute of Technology, Boston, MA 02139, USA
1 shared publication - Effie Efthimia Bastounis
Institute for Biology, Humboldt-Universität zu Berlin, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 19 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
SCGB1D2 inhibits growth of Borrelia burgdorferi and affects susceptibility to Lyme disease
Lyme disease is a tick-borne disease caused by bacteria of the genus Borrelia. The host factors that modulate susceptibility for Lyme disease have remained mostly unknown. Using epidemiological and genetic data from FinnGen and Estonian Biobank, we identify two previously known variants and an unknown common missense variant at the gene encoding for Secretoglobin family 1D member 2 (SCGB1D2) protein that increases the susceptibility for Lyme disease. Using live Borrelia burgdorferi (Bb) we find that recombinant reference SCGB1D2 protein inhibits the growth of Bb in vitro more efficiently than the recombinant protein with SCGB1D2 P53L deleterious missense variant. Finally, using an in vivo murine infection model we show that recombinant SCGB1D2 prevents infection by Borrelia in vivo. Together, these data suggest that SCGB1D2 is a host defense factor present in the skin, sweat, and other secretions which protects against Bb infection and opens an exciting therapeutic avenue for Lyme disease.
- 19 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessSCGB1D2 inhibits growth of Borrelia burgdorferi and affects susceptibility to Lyme disease
Lyme disease is a tick-borne disease caused by bacteria of the genus Borrelia. The host factors that modulate susceptibility for Lyme disease have remained mostly unknown. Using epidemiological and genetic data from FinnGen and Estonian Biobank, we identify two previously known variants and an unknown common missense variant at the gene encoding for Secretoglobin family 1D member 2 (SCGB1D2) protein that increases the susceptibility for Lyme disease. Using live Borrelia burgdorferi (Bb) we find that recombinant reference SCGB1D2 protein inhibits the growth of Bb in vitro more efficiently than the recombinant protein with SCGB1D2 P53L deleterious missense variant. Finally, using an in vivo murine infection model we show that recombinant SCGB1D2 prevents infection by Borrelia in vivo. Together, these data suggest that SCGB1D2 is a host defense factor present in the skin, sweat, and other secretions which protects against Bb infection and opens an exciting therapeutic avenue for Lyme disease.
- Open Access
Borrelia burgdorferi modulates the physical forces and immunity signaling in endothelial cells
- 15 March 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (6) , 1371-1377
CD47 Blockade Leads to Chemokine-Dependent Monocyte Infiltration and Loss of B Cells from the Splenic Marginal Zone
CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein α (SIRPα). Therapeutic blockade of CD47–SIRPα interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47–SIRPα interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47–SIRPα interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2+Ly6Chi monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells. Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.
- 15 March 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (6) , 1371-1377
CD47 Blockade Leads to Chemokine-Dependent Monocyte Infiltration and Loss of B Cells from the Splenic Marginal Zone
CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein α (SIRPα). Therapeutic blockade of CD47–SIRPα interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47–SIRPα interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47–SIRPα interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2+Ly6Chi monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells. Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.